BlackRock Investment Management’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

BlackRock Investment Management’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-147	Closed	-$60K	–	3991
2016 Q3	$60K	Sell	147 -13	-8%	-$5.81K	﹤0.01%	3289
2016 Q2	$78K	Sell	160 -63	-28%	-$32K	﹤0.01%	3316
2016 Q1	$115K	Sell	223 -31	-12%	-$17.3K	﹤0.01%	3227
2015 Q4	$200K	Hold	254	–	–	﹤0.01%	3230
2015 Q3	$349K	Hold	254	–	–	﹤0.01%	3140
2015 Q2	$511K	Buy	+254	New	+$649K	﹤0.01%	3118

Other funds holding HTGM

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SIM

Sonora Investment Management Tucson, Arizona $798M AUM 17.61% 1-Year Est. Return

Ironwood Financial Tucson, Arizona $639M AUM 19.03% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlackRock Investment Management's HTGM Position: Q4 2016 in Review

BlackRock Investment Management sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q4 2016, closing a stake of 147 shares — an estimated $60K sold.

BlackRock Investment Management first reported a position in HTGM in Q2 2015 and held it in 6 quarters. The position peaked at $511K in Q2 2015. 13 funds tracked by Wall St. Rank hold HTGM as of Q4 2016.

BlackRock Investment Management reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
BlackRock Investment Management sold 147 HTG Molecular Diagnostics, Inc. Common Stock shares in Q4 2016, an estimated $60K.
BlackRock Investment Management first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q2 2015 and held it in 6 quarters.
BlackRock Investment Management's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $511K in Q2 2015.
13 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.